The relationship between infection and standard prescription antibiotics

Could CBD be useful in the fight against resistant bacterial strains? The arise from the University of Queensland in Australia suggest that it is possible. However prior to examining the research study in depth, it is useful to understand the evolution of the relationship between bacteria and prescription antibiotics.

Since the innovative discovery of penicillin by Alexander Fleming in 1928, prescription antibiotics have been a vital tool in the fight against bacteria and infections. And although we still utilize the very same proven approaches today, bacteria have developed. When exposed to prescription antibiotics, particular bacteria, fungis and parasites are able to adjust and cancel the efficiency of the drug by developing resistance.

It’s worth pointing out that antimicrobial resistance was likely to happen anyhow, as the hereditary code for bacteria modifications in time. Nevertheless, it is thought that the overuse of prescription antibiotics is an essential factor that speeds up the development of resistant strains.

According to the World Health Organization, antimicrobial resistance “is a significantly severe threat to worldwide public health that needs action in all sectors of government and in society.” This has actually led researchers to believe outside the box by attempting to recognize substances that could be beneficial in the fight against harmful bacteria. Among these substances is cannabidiol (CBD oceanic), a cannabinoid found in Cannabis sativa.

Researchers are searching for brand-new ways to assault infections and resistant bacteria.

Dr. Mark Blaskovich, Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery and Senior Research Officer at the Institute for Molecular Bioscience at the University of Queensland, concluded that provision CBD works against Gram-positive bacteria. Strains of Gram-positive bacteria consist of Staphylococcus aureus (typical in skin infections) and Streptococcus pneumoniae (typical in bacterial pneumonia).

Dr. Blaskovich presented his findings at a yearly conference of the American Society for Microbiology. In vitro samples of both kinds of gram-positive bacteria were treated with artificial CBD. The outcomes led Dr. Blaskovich to the conclusion that CBD works at levels comparable to those of prescription antibiotics vancomycin and daptomycin. He also found that CBD appeared to work against gram-positive strains of resistant bacteria, which numerous traditional prescription antibiotics are starting to stop working.

” In particular, the activity was picked against the resistant strains of Staphylococcus aureus (MRSA, VISA, SARV), Streptococcus pneumoniae (MDR), and Enterococcus faecalis (ERV). Cannabidiol was bactericidal, had a low tendency to induce resistance and was active against MRSA biofilms. “

The group also conducted another research study utilizing topical CBD to treat a skin infection in mice. Once again, although the outcomes were positive, CBD did not appear to remove the infection, but just to decrease the variety of bacterial cells.

Could CBD become an antibiotic?

While it is easy to hail this work as a substantial development in the anti-bacterial abilities of CBD, it is prematurely to quit on penicillin.

Although it is thought that the efficiency of CBD might originate from the method it assaults the biofilm surrounding bacterial cells, the authors are still uncertain of the system of action of CBD. They also did not think twice to mention the drawbacks of the research study. Dr. Blaskovich pointed out that given that the outcomes are in the initial stages, it is far too early for individuals to start treating their CBD infections themselves.

The research study was also conducted in vitro (outside the body), and there is a danger that the outcomes of clinical trials will not be the same. A number of substances have shown anti-bacterial efficacy in petri meals, but then failed at this crucial phase. It must also be mentioned that the two research studies were performed in cooperation with Botanix Pharmaceuticals Ltd, a pharmaceutical business focusing on topical CBD products.

Nevertheless, this research could be an essential step forward for CBD and the fight against antimicrobial resistance. CBD continues to have a good safety profile and is ruled out toxic even in large quantities. Fortunately, Dr. Blaskovich and his group strategy to continue their research.

Scroll to top